Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Documented initial diagnosis of multiple myeloma according to International Myeloma
Working Group (IMWG) diagnostic criteria.
- Part 1 and 2: Participant could not tolerate or has disease that is relapsed or
refractory to established therapies, including the last line of therapy. Part 3: (a)
Relapsed or refractory disease, and exposed to a PI, IMiD, and an anti-CD38 mAb; (b)
Documented evidence of progressive disease based on inve.stigator's determination of
response by IMWG criteria on or after their last regimen
Part 1 and Part 2:
- Eastern Cooperative Oncology Group (ECOG) performance status grade
of 0 or 1 at screening and immediately before the start of study drug administration.
Part 3: ECOG performance status grade of 0, 1, or 2 at screening and immediately
before the start of study drug administration.
Exclusion Criteria:
All Parts:
- Targeted therapy, epigenetic therapy, or treatment with an investigational
treatment or an invasive investigational medical device within 21 days or at least 5
half-lives, whichever is less. Part 3: prior BCMA targeted bispecific antibody
therapy; prior GPRC5D targeted therapy.
- Allogeneic stem cell transplant within 6 months before the first dose of
study treatment.
- Central nervous system involvement or clinical signs of meningeal
involvement of multiple myeloma.
- Active plasma cell leukemia (greater than [>]2.0*10^9/L plasma cells by
standard differential), Waldenstro?m's macroglobulinemia, POEMS syndrome
(polyneuropathy, organomegaly, endocrinopathy, M- protein, and skin changes), or
primary amyloid light chain amyloidosis.
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 10/2/23. Questions regarding updates should be directed to the study team contact.